Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eylea vs Laser in Retinopathy of Prematurity (FIREFLEYE)
NCT04004208Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2019
- Primary completion
- Feb 2021
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 27
01
Overview
A Phase 3 trial of aflibercept in retinopathy of prematurity (ROP), sponsored by Bayer. Started Sep 2019; status: completed.
02
Drugs
aflibercept
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT04004208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04004208.